A Phase IV Double Blind Randomised Controlled Trial (DBRCT) to Investigate the Effect of PCV-13 and PPV-23 on Pneumococcal Colonisation Using the Experimental Human Pneumococcal Challenge (EHPC) Model in Healthy Adults
Latest Information Update: 09 Jan 2023
Price :
$35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 23-valent vaccine Walvax Biotechnology (Primary)
- Indications Pneumonia
- Focus Therapeutic Use
- Acronyms Pneumo 2; PREVENTING PNEUMO 2
- 03 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 03 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Jul 2023.
- 02 Jan 2023 Status changed from recruiting to completed.